WASHINGTON- Drug regulators gave the go ahead on Friday for a blood cancer medicine by Seattle Genetics Inc, making it the first drug for Hodgkin's lymphoma approved in more than 30 years.
The Food and Drug Administration approved Seattle Genetics' Adcetris to treat two types of relatively rare
